AKZO NOBEL

PRESS RELEASE

CORPORATE MEDIA RELATIONS

FDA says tibolone not approvable as a menopause treatment in the U.S.

Arnhem, the Netherlands, June 2, 2006 —The U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) submitted for tibolone by Akzo Nobel's human healthcare business, Organon, is "not approvable".

This response follows an amendment to the NDA which Organon filed with the FDA in December 2005. Organon plans to withdraw the application for tibolone as a treatment for women in the United States with menopausal symptoms.

"Although Organon is disappointed with the FDA's response, we will continue to be committed to this proven brand," said Toon Wilderbeek, General Manager of Organon and member of Akzo Nobel's Board of Management responsible for Pharma. "Tibolone is available all over the world in countries outside the U.S. where it has been approved and marketed for nearly 20 years."

- - -

Note for the editor

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments – human and animal health, coatings and chemicals – subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the second quarter will be published on July 20, 2006.

Internet: www.akzonobel.com; www.organon.com

Not for publication – for more information

Akzo Nobel nv
Corporate Media Relations, tel. +31 26 366 43 43, contact: Marc Michelsen
Organon Inc., tel. +1 973 325 5353, contact: Fran Desena

Safe Harbor Statement*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com. The 2005 Annual Report on Form 20-F will be available at the end of the second quarter of 2006.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.

Akzo Nobel nv
Velperweg 76
P.O. Box 9300
6800 SB Arnhem
The Netherlands
Tel +31 26 366 43 43
Fax +31 26 366 49 40